Medically reviewed on March 7, 2018.
Applies to the following strengths: 50 mg; 25 mg; 100 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
Usual dose: 100 mg orally once a day
Comments: When used in combination with an insulin secretagogue (e.g. sulfonylurea) or insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.
Use: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Renal Dose Adjustments
Mild renal impairment (eGFR 45 mL/min/1.73 m2 or greater): No adjustment recommended
Moderate renal impairment (eGFR 30 mL/min/1.73 m2 to less than 45 mL/min/1.73 m2): 50 mg orally once a day
Severe renal impairment (eGFR less than 30 mL/min/1.73 m2): 25 mg orally once a day
Liver Dose Adjustments
Mild or moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Use caution; no data available
-Hypersensitivity to this drug or any of the product excipients
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Hemodialysis: 25 mg orally once a day
Peritoneal dialysis: 25 mg orally once a day
-May be administered without regard to timing of dialysis
-May take with or without food
-Missed doses should be taken as soon as the patient remembers. More than one dose should not be taken on the same day.
-May be used as monotherapy and combination therapy in adults with type 2 diabetes mellitus.
-Not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.
-Has not been studied in patients with a history of pancreatitis; it is unknown whether these patients may be at an increased risk for the development of pancreatitis.
-Monitor for signs and symptoms of pancreatitis
-Monitor glycemic control
-Obtain baseline renal function tests and monitor periodically during therapy; elderly patients should be assessed more frequently
-Instruct patient to report signs and symptoms of pancreatitis; if persistent, severe abdominal pain occurs, seek medical advice promptly.
-Serious allergic reactions may occur; if symptoms occur, seek medical advice promptly.
-Hypoglycemia may occur, more commonly when used in combination with insulin or a sulfonylurea.
-Patients should understand the importance of adhering to dietary instructions and regular physical activity; during periods of stress such as fever, trauma, infection, or surgery, management of diabetes may change and patients should be advised to seek medical advice.
-Instruct patients to contact their health care provider if they develop severe and persistent joint pain.
-Instruct patients to contact their health care provider if they develop signs or symptoms of heart failure.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about sitagliptin
- Sitagliptin Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- Support Group
- En Español
- 80 Reviews
- Drug class: dipeptidyl peptidase 4 inhibitors
Other brands: Januvia